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1. FOREWORD-WITH A REVIEW OF THE PAST EXPERIENCES OF THE YALE
POLIOMYELITIS STUDY UNIT WITH ORAL POLIOVIRUS VACCINES**
Early in 1961 a city-wide oral poliomyelitis vaccination program was under-
taken in the city of Middletown, Connecticut by the Department of
Epidemiology and Public Health of the Yale University School of Medicine,
working in close collaboration with the Director of Health of Middletown,
Dr. M. L. Palmieri, and his staff. A description of various aspects of this
so-called mass vaccination project follows in the papers that make up this
issue of THE YALE JOURNAL OF BIOLOGY AND MEDICINE.
In the Middletown program some 10,000 children under the age of 18
received oral poliovirus vaccine (Sabin strains) in two doses: the first
given in January 1961, consisting of monovalent vaccine containing Type I
poliovirus, and the second six weeks later, in March 1961, a bivalent
vaccine containing polioviruses types II and III. The study is the culmin-
ation of a six-year program concerned with oral poliovirus vaccines in
which the Yale Poliomyelitis Study Unit has been engaged since the Sabin
attenuated poliovirus strains first became available to us in 1955.t Of
the several trials of oral vaccination which this Unit has conducted, this
has been the largest we have attempted and one which has benefited
from both our own previous experiences and those of others whose reports
have been accumulating rapidly during the past two or three years.
By and large, the general objective of the Yale Poliomyelitis Study
Unit has been to observe and study carefully what happens to a population
when some of its members are artificially infected (vaccinated) with
attenuated poliovirus strains and others are intimately exposed to in-
dividuals so infected. In other words, we have regarded these trials in
large part as a setting for work in experimental epidemiology, with the
rare opportunity to do freely in man what previously, in the study of other
diseases, has been possible only in populations of animals or birds. Thus
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we have had as a major objective the accumulation of information and
knowledge with regard to the ecology of infection in man caused by
attenuated poliomyelitis viruses.
In most of our previous trials we have not attempted to assume
responsibility for immunizing a given population as a public health measure.
This, we believe, is more properly the function of a city or state public
health department or agency. The role of a university epidemiological
department in this situation is rather a more scientific one, although the
Yale studies have not all been of a theoretical nature. They have had their
practical aspects, for obviously our study unit has been concerned with the
search for and the development of new and improved methods of im-
munization against poliomyelitis. Nearly all previous trials have required
some teamwork, in which the participation and cooperation of various
agencies or individuals, many of them health officers, has been extensive.
During the past five years there has been no dearth of trials and studies
by others on both the broader public health aspects and the experimental
aspects of oral vaccination against poliomyelitis. These are not only exempli-
fied in the investigations of Dr. Sabin himself' but in the very extensive work
done in the Soviet Union' and its satellite countries,' which was reviewed
firsthand in 1959 by Dr. Dorothy M. Horstmann of this Department,' and
by the proponents ofthe Koprowski' and Lederle' oral vaccines, as well as by
many others.7" While the experimental aspects of oral vaccine' have not
been neglected, they have not received the attention they deserve. There
is plenty to be learned here; in fact, a decade or more of research on this
subject still lies before us.
Early work on oral poliovirus vaccine by the Yale Poliomyelitis Research
Unit (1956-1958)" was carried on largely within an institution at South-
bury, Connecticut.* In the beginning, we were much concerned with the
safety of the vaccine and possible evidences of illness in the vaccinees.
Such institutional trials were conducted under strict isolation precautions.
We vaccinated small numbers at first and proceeded cautiously. Both
vaccinees and their contacts were kept in isolation, and all bedding and
* It would be impossible to mention the names of more than a very few who deserve
our gratitude. For support of many of the studies carried out in Connecticut we are
indebted to the former State Commissioner of Health, Dr. Stanley Osborn, and the
present Commissioner, Dr. Franklin M. Foote; also to Dr. James Hart, Director of
Communicable Disease Control and to Dr. Mila Rindge, Epidemiologist of the
Connecticut State Department of Health. The names of others who have helped us
on individual projects have been listed in various published reports describing individual
trials which the Study Unit has carried out.`0'7 However, particularly high on this list
are Dr. Grover F. Powers, Professor Emeritus of Pediatrics in the Yale University
School of Medicine and Dr. Hermann Yannet, Director of the Training School at
Southbury, Connecticut.
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utensils used in the cottages were sterilized. Immune responses to oral
vaccination were measured, and surveys were conducted to determine the
capacity of the attenuated viruses to spread within the institution to
intimate and less intimate associates among both juvenile and adult groups.'
Also we made one of the earliest studies on genetic markers of poliovirus
strains recovered from vaccinees as a means of detecting possible indications
of reversion to a more virulent form. In addition, we encountered early in
1956 a previously undescribed phenomenon, namely that of "local
alimentary tract immunity," which has played such an important part in
subsequent decisions as to what the oral vaccine might be expected to
accomplish over and above its capacity to confer serological immunity on
individual vaccinees. This phenomenon came out particularly when oral
poliovirus vaccine was given to two groups of individuals: a) those whose
antibodies had been derived from the Salk-type vaccine, and b) those
whose antibodies had been acquired naturally from inapparent infection
with wild polioviruses. The first group proved easy to infect with homotypic
attenuated polioviruses; the second, however, was much more resistant to
what was obviously a reinfection with homotypic poliovirus. This phenome-
non of local (alimentary) resistance, which deserves much more work, has
been ascribed to an inability of polioviruses to gain much of a foothold in an
alimentary tract which previously has been the site of homotypic viral
multiplication.
On the basis of the existence of this phenomenon of intestinal resistance,
the claim has been made that following mass use of oral vaccine, not only
are individuals immunized, but a kind of community-wide intestinal
immunity can be established, thus making it possible to break the chain
of transmission and eliminate polioviruses from sizeable communities.
Subsequent to the Southbury studies we ventured outside the confines
of an institution and began a series of village trials to enable us to study
effects of the oral vaccine when given under natural conditions in an
open community. Communities with sanitation of a relatively low order
were first chosen: an American-Indian village in southern Arizona,"'14
and a village in Costa Rica, C.A.' 1 In the latter study we had our first
opportunity to deal with children who had not previously received the
Salk-type vaccine. Also, because the Costa Rican Ministry of Health was
starting a campaign using an oral poliovirus vaccine composed of the
Lederle strains, we used the Lederle vaccine for the first and only time
instead of that made from the Sabin strains of attenuated polioviruses.
This is not the time nor place to record and discuss many of the interesting
aspects of the studies in these two (Arizona and Costa Rican) trials. We
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were confronted in both with a population of young children, some of whom
were highly immune, and we were able to observe that a high level of
immunity in the local community curtailed the spread of attenuated
poliovirus infection. In both villages we encountered the difficult problem
posed by the presence of competing enteroviruses and the various degrees
of interference with vaccine "takes" which some of them cause. We were
also able, in both villages, to observe the manner in which local flies pick
up enteroviruses during a vaccine trial."'6 These insects are capable of
spreading virulent polioviruses and presumably are also capable of spread-
ing attenuated polioviruses, thus serving as immunizing agents, if you will.
Continuing somewhat along this line we had, in 1960, the opportunity
of carrying out an extensive trial in some 350 preschool children in New
Haven.'7 The medical profession in this city, the Health Department, and
the Visiting Nurse Association were sympathetic and helpful, and the
population chosen for the trial reacted favorably to the idea of live polio-
virus vaccine. It thus proved possible (and indeed feasible) to carry out
this urban trial with meticulous care, as a kind of clinical investigation
under university auspices assisted by community health agencies.
For some years it has been apparent that not only are preschool children
less accessible for the administration of the Salk-type vaccine than are
children of school age, but biologically they do not respond as well to such
inactivated antigen in so far as the development and maintenance of anti-
bodies is concerned. In the New Haven trial we were particularly concerned
with the 0-5 year age group of low socio-economic status. This hard-to-
reach preschool group has some epidemiological significance, since in any
population young children are the most readily infected and are also
the chief spreaders of polioviruses. Also, it is in young children that most
of the paralytic cases now occur, for the age distribution of poliomyelitis
in the United States has returned to what amounts to the old-fashioned
"infantile paralysis." This was true of the 1959 poliomyelitis epidemic
in New Haven, and many similar recent epidemics in the United States.
Thus there were important reasons for determining how completely and
effectively one could reach and immunize a preschool group. Papers
II-VI and VIII in the Middletown series should be viewed in this light.
Another problem of practical importance considered in the New Haven
Study was that of testing the comparative merits of three different dosage
schedules: a) three monovalent vaccines given in three doses one month
apart in the order type I, type III, type II; b) monovalent type I vaccine,
followed six weeks later by bivalent types II and III; and c) trivalent
vaccine given twice, six weeks apart. All three of these schedules proved
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to be almost equally (and highly) effective in producing antibodies to the
three types, with the antibody levels showing only slight decline after one
year. Although there was little to choose among the different schedules on
immunological grounds, certainly there is a practical advantage in using
two doses instead of three.
In testing the pre- and post-vaccinal immune status of the children in
the New Haven trial, we used for the first time in the field, a micro-method
for the determination of neutralizing antibodies, devised by Drs. R. Green
and E. M. Opton of this department."8 This method proved to have an
enormous advantage when it came to bleeding young infants in the home.
Also, community environmental studies were carried out by examining
for poliovirus, sewage samples from some of the housing projects where
children participating in the vaccine trial lived. This was done to determine
how long the attenuated poliovirus strains remained in a community of
this type and size. Such information was correlated with data on individual
excretion rates as determined by testing weekly rectal swabs from each
vaccinee.
Another important recent project has dealt with post-oral vaccinal
viremia in young children. Following some preliminary observations in
the New Haven trial, we were fortunate to be able to continue this study
at the New York Foundling Hospital* in children who had not received
Salk-type vaccine. The objective was to see if viremia could be detected
in "triple-negative" subjects after the ingestion of each of the three Sabin
strains of oral poliovirus vaccine. Previous studies by others had indicated
that the Lederle type I and the Sabin type II strains did give rise now and
again to viremia and that such viruses were more readily recovered post-
vaccinally from the blood of individuals lacking antibodies to all three types.
In brief, the results of these incomplete studies have been clear-cut and
informative. Of 22 triple-negative children, age 5 to 18 months, 21 were
found to have become infected after ingestion of Sabin type I vaccine,
but virus was not detected in the blood of any child, nor was "bound"
viremia (virus + antibody) detected in any of the 66 specimens tested.
In considerable contrast were the results with type II. Twenty-two
triple-negative children were fed type II vaccine, and all became infected.
"Free" viremia was detected in 11 (50 per cent) and "bound" viremia
in an additional eight (36 per cent). No viremia was detected in 17 children
infected with type III poliovirus. The significance of the finding of type II
* We are most grateful for permission and helpful assistance in this as yet unpublished
work to Dr. Alfred Vignec, Medical Director of the New York Foundling Hospital
and a former member (1938-1940) of the Yale Poliomyelitis Study Unit.
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viremia in vaccinees is not entirely clear. Presumably, in view of the field
data on safety, it is an expression of rather extensive extraneural multipli-
cation of a strain which nevertheless has an extremely low neurotropic
capacity.
The Middletown trial and comparable trials by other groups. With the
background of the experiences described above, the Yale Poliomyelitis
Study Unit undertook the Middletown trial, essentially to test the feasability
and effectiveness of a city-wide mass vaccination project. Prior to the
initiation of the study, there had been a number of so-called mass vaccination
trials in which, within a relatively few days, oral vaccine was administered
on a city-wide scale to large numbers of preschool and school-aged chil-
dren. In connection with these trials, some of the reasons for the use of
oral poliovirus vaccine on a simultaneous mass basis have been discussed.
They are numerous. It is administratively advantageous to give the
vaccine to those age groups designated as more susceptible, in a short
campaign lasting but a few days rather than to administer it to all age
groups over a period of weeks, months, or years. It is easier to reach more
individuals who need vaccination in this way. Enthusiasm can be stirred
by a community campaign urging people to take the vaccine, whereas
such enthusiasm may not exist under other circumstances. There are also
epidemiological reasons for the quick flooding, as it were, of the population
of a given city with one type of attenuated poliovirus at a time. By this
means it is possible to avoid problems of interference between types of
polioviruses; indeed, if two or three poliovirus types are being administered
sporadically to various groups of the same population, a certain amount of
interference among the three types may be expected to occur. This might
result in vaccination failures in some instances.
The part to be played by the health officer in the many administrative
problems connected with any mass program of oral poliovirus vaccine
administration is an extremely important one. Later, after the mass
campaign has been completed, it is necessary to maintain the level of
immunization within a given population by vaccinating infants born into
the community; the practicing physician assumes a position of first im-
portance in this second phase.
Of the other city-wide trials conducted in this country in 1960 during
the inter-epidemic period, Dr. Sabin's trial in Cincinnati has been a most
important one.'9 This involved a large population group of some 300,000
people, most of whom were under the age of 18. Monovalent vaccine
was used; the first dose (type I) was given in the late spring of 1960
(May-June) and the others (types III and II) sequentially in the fall
444
Volume 34, April 1962Foreword PAUL
so that the campaign of mass vaccination actually lasted six months. The
Cincinnati study included a careful system of surveillance and extensive
laboratory work on a sample of the vaccinated population. It was a trial
conducted largely under university auspices with the cooperation of the
local health department.
The Rochester trial, in which the Sabin strains were used, was essen-
tially under municipal health department auspices.' The objective here was
somewhat different in that the program did not call for such extensive
laboratory tests as were carried out in the Cincinnati study; essentially
it was a practical demonstration of the health department's role in the
task of vaccinating a population with this new form of immunizing agent.
Other city-wide trials carried out in 1960 in the United States, using the
Lederle strains, include one in Miami, Florida, and various trials in
Minnesota.
Consequently it was with a background of some experience gained both
by ourselves and by others that the Middletown oral vaccine trial was
embarked upon early in 1961. How nearly it met its objectives and what
was learned can be found in the following reports.
Too much emphasis cannot be laid upon the teamwork required in
investigations of this kind. The selection of names of various members of
the Yale Poliomyelitis Study Unit and other assistants as authors of the
papers which follow was far from easy. A great many people did a great
deal of work in this project; some of them are not given credit so that
it would be more realistic to say that these papers are by the Yale Polio-
myelitis Study Unit, the Middletown Department of Health, and many
other friends.
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